Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06046482 |
|
Recruitment Status :
Suspended
(PI Request)
First Posted : September 21, 2023
Last Update Posted : April 12, 2024
|
Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Suspended |
|---|---|
| Estimated Primary Completion Date : | November 30, 2027 |
| Estimated Study Completion Date : | November 30, 2029 |